Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
GM-CSF DID NOT ALLOW DOXORUBICIN DOSE-ESCALATION IN THE MAID REGIMEN - A PHASE-I TRIAL - A SOUTHWEST-ONCOLOGY-GROUP STUDY
Autore:
HICKS LG; BALCERZAK SP; ZALUPSKI M;
Indirizzi:
OHIO STATE UNIV,MED CTR,410 W 10TH AVE,N1021 DOAN HALL COLUMBUS OH 43210 OHIO STATE UNIV,MED CTR COLUMBUS OH 43210 WAYNE STATE UNIV,HARPER GRACE HOSP,DIV MED ONCOL DETROIT MI 48201
Titolo Testata:
Cancer investigation
fascicolo: 6, volume: 14, anno: 1996,
pagine: 507 - 512
SICI:
0735-7907(1996)14:6<507:GDNADD>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; CHEMOTHERAPY-INDUCED MYELOSUPPRESSION; SOFT-TISSUE SARCOMAS; MARROW TRANSPLANTATION; RANDOMIZED TRIAL; HUMAN NEOPLASIA; GRANULOCYTE; ADRIAMYCIN; CANCER; DACARBAZINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
29
Recensione:
Indirizzi per estratti:
Citazione:
L.G. Hicks et al., "GM-CSF DID NOT ALLOW DOXORUBICIN DOSE-ESCALATION IN THE MAID REGIMEN - A PHASE-I TRIAL - A SOUTHWEST-ONCOLOGY-GROUP STUDY", Cancer investigation, 14(6), 1996, pp. 507-512

Abstract

Since dose intensity of doxorubicin is correlated with the clinical response of patients with soft tissue sarcomas and since doxorubicin dose intensity may be compromised in combination chemotherapy, we evaluated the use of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) to ameliorate myelosuppression and allow doxorubicin dose escalation in a phase 1 trial utilizing the MAID combination [Mesna 2.5 g/m(2)/day x 4 days, Adriamycin (doxorubicin) 15 mg/m(2)/day x 4days, ifosfamide 2.0 g/m(2)/day x 3 days, dacarbazine 250 mg/m(2)/dayx 4 days; to be repeated every 21 days]. Thirteen patients were treated. The doxorubicin dose for the first 6 patients was at the standard dose of 15 mg/m(2)/day x 4 days (level 1), while the doxorubicin dose for the next 7 patients was escalated by 25% to 18.75 mg/m(2)/day x 4 days (level 2). rGM-CSF was given at 5 mu g/kg/day, days 5-14. All patients experienced moderate to severe myelosuppression, with all patients at dose level 2 requiring doxorubicin dose reduction to dose level 1 or lower by their third course of treatment. rGM-CSF failed to allowsustained escalation of the doxorubicin dose in the MAID regimen.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 12:57:25